ProAmpac Celebrates Trio of Honors at 2024 AmeriStar Awards
5.9.2024 17:45:00 CEST | Business Wire | Press release
ProAmpac, a leader in flexible packaging and material science, is thrilled to announce its recognition at the 2024 AmeriStar Awards, securing two wins in the Sustainable Packaging category and contributing to a third recognition for an innovative e-commerce solution. The accolades showcase ProAmpac's dedication to sustainability and innovation with the RAP Sandwich Wedge for Sammi's; ProActive Recyclable RP-1000 Paper Series for Marks & Spencer's organic potatoes; and the insulated paper bag known as ProActive Recyclable FiberCool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905477309/en/
Sammi's RAP Sandwich Wedge (Photo: Business Wire)
"The recognition by AmeriStar reflects our relentless pursuit of innovative and sustainable packaging solutions," said Chad Murdock, president of the fiber division at ProAmpac. "We're honored to have our efforts acknowledged, especially as we continue to advance in areas like the fiberization of packaging that contribute to a more circular economy."
Developed for Sammi’s grab-and-go sandwiches, the high-barrier RAP Sandwich Wedge, with a premium shelf appearance, utilizes a fiber-based carton board with a transparent window. This innovative solution employs modified atmosphere packaging, optimizing product preservation and visibility while maintaining very low oxygen levels for extended shelf life and decreased food waste.
Designed for Marks & Spencer’s organic potatoes, ProAmpac’s second award-winning innovation, the ProActive Recyclable® RP-1000 Paper Series, offers superior robustness and a premium natural look for packing organic potatoes. This fully recyclable packaging has premium sealant technology for running at rate on high-speed form-fill-seal equipment and is curbside recyclable in the UK, while also being FSC-certified for responsible sourcing.
"Our technical team is at the forefront of fiber packaging innovation across diverse markets," said Lynsey Maddison, director of product development at ProAmpac. "We are committed to advancing these technologies to help our customers achieve more sustainable packaging solutions. As we continue to explore new applications and improvements, our goal remains to drive impactful, eco-friendly advancements in the industry.”
In addition to these two awards, ProAmpac contributed to a win in the Packaging that Saves Food category with the ProActive Recyclable FiberCool, an insulated paper bag for e-commerce delivery. This fiber-based, curbside-recyclable solution replaces a bulky traditional multi-package system, reducing packaging weight and drastically enhancing thermal retention. “Our work on FiberCool exemplifies how we can innovate to meet the growing demand for sustainable packaging without compromising on performance,” said Ray Recchia, global innovation manager at ProAmpac. “By improving thermal insulation, we help reduce food spoilage and waste, giving customers more flexibility with their groceries after delivery,” adds Recchia.
As ProAmpac continues to innovate, it remains dedicated to enhancing sustainability and product performance. For more information on ProAmpac’s award-winning packaging solutions, visit ProAmpac.com or contact Marketing@ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905477309/en/
Contacts
Whitney Miles
Whitney Miles
ProAmpac
(617) 721-7040
Whitney.Miles@ProAmpac.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom